189 related articles for article (PubMed ID: 35478147)
1. Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer.
Kumagai Y; Futoh Y; Miyato H; Ohzawa H; Yamaguchi H; Saito S; Kurashina K; Hosoya Y; Lefor AK; Sata N; Kitayama J
In Vivo; 2022; 36(3):1126-1135. PubMed ID: 35478147
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Kim W; Chu TH; Nienhüser H; Jiang Z; Del Portillo A; Remotti HE; White RA; Hayakawa Y; Tomita H; Fox JG; Drake CG; Wang TC
Gastroenterology; 2021 Feb; 160(3):781-796. PubMed ID: 33129844
[TBL] [Abstract][Full Text] [Related]
3. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
4. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
[TBL] [Abstract][Full Text] [Related]
5. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.
Küçükköse E; Heesters BA; Villaudy J; Verheem A; Cercel M; van Hal S; Boj SF; Borel Rinkes IHM; Punt CJA; Roodhart JML; Laoukili J; Koopman M; Spits H; Kranenburg O
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36543378
[TBL] [Abstract][Full Text] [Related]
6. [Intraperitoneal Transfer of miR-29b Containing Exosome Suppresses the Development of Peritoneal Metastases from Gastric Cancer].
Kimura Y; Ohzawa H; Kaneko Y; Miyato H; Kurashina K; Saito S; Yamaguchi H; Hosoya Y; Sata N; Kitayama J
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1435-1437. PubMed ID: 38303299
[TBL] [Abstract][Full Text] [Related]
7. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer.
Fujimori D; Kinoshita J; Yamaguchi T; Nakamura Y; Gunjigake K; Ohama T; Sato K; Yamamoto M; Tsukamoto T; Nomura S; Ohta T; Fushida S
BMC Cancer; 2020 Oct; 20(1):1014. PubMed ID: 33081727
[TBL] [Abstract][Full Text] [Related]
8. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Bekos C; Pils D; Dekan S; Hofstetter G; Horak P; Reinthaller A; Polterauer S; Schwameis R; Aust S
Sci Rep; 2021 Mar; 11(1):6400. PubMed ID: 33737722
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal transfer of microRNA-29b-containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer.
Kimura Y; Ohzawa H; Miyato H; Kaneko Y; Kuchimaru T; Takahashi R; Yamaguchi H; Kurashina K; Saito S; Hosoya Y; Lefor AK; Sata N; Kitayama J
Cancer Sci; 2023 Jul; 114(7):2939-2950. PubMed ID: 36939028
[TBL] [Abstract][Full Text] [Related]
10. Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.
Tabuchi M; Kikuchi S; Tazawa H; Okura T; Ogawa T; Mitsui E; Une Y; Kuroda S; Sato H; Noma K; Kagawa S; Ohara T; Ohtsuka J; Ohki R; Urata Y; Fujiwara T
Mol Ther Oncol; 2024 Jun; 32(2):200806. PubMed ID: 38745748
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8
Masuda C; Morinaga M; Wakita D; Yorozu K; Kurasawa M; Sugimoto M; Kondoh O
Clin Exp Metastasis; 2022 Apr; 39(2):335-344. PubMed ID: 34797455
[TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.
Guo Z; Wang X; Cheng D; Xia Z; Luan M; Zhang S
PLoS One; 2014; 9(2):e89350. PubMed ID: 24586709
[TBL] [Abstract][Full Text] [Related]
13. Vagus nerve signal has an inhibitory influence on the development of peritoneal metastasis in murine gastric cancer.
Futoh Y; Miyato H; Yamaguchi H; Matsumiya M; Takahashi R; Kaneko Y; Kimura Y; Ohzawa H; Sata N; Kitayama J; Hosoya Y
Sci Rep; 2024 Apr; 14(1):7832. PubMed ID: 38570542
[TBL] [Abstract][Full Text] [Related]
14. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
16. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
17. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
19. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
20. Altered intraperitoneal immune microenvironment in patients with peritoneal metastases from gastric cancer.
Takahashi K; Kurashina K; Yamaguchi H; Kanamaru R; Ohzawa H; Miyato H; Saito S; Hosoya Y; Lefor AK; Sata N; Kitayama J
Front Immunol; 2022; 13():969468. PubMed ID: 36119051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]